Statin therapy is associated with reduced neuropathologic changes of alzheimer disease

Neurology

Volumn 70, Issue 24, 2008, Pages 2349-2350

  Golomb, Beatrice A ^a   Evans, Marcella A ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; UBIDECARENONE;

ALZHEIMER DISEASE; CLINICAL TRIAL; HUMAN; NOTE; PATHOLOGY; HORMONE SUBSTITUTION; LETTER; MORBIDITY; MORTALITY; NERVE DEGENERATION; NEUROPATHOLOGY; NEUROPROTECTION; NEUROTOXICITY; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; UNSPECIFIED SIDE EFFECT;

ALZHEIMER DISEASE; CLINICAL TRIALS AS TOPIC; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;

EID: 46049109962     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/01.wnl.0000317006.87071.b1     Document Type: Letter

References (12)

1. Li G, Larson EB, Sonnen JA, et al. Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease. Neurology 2007;69:878-885.
2. Golomb BA, Jaworski BA. Statins and dementia. Arch Neurol 2001;58:1169-1170.
3. Zandi PP, Carlson MC, Plassman BL, et al. Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study. JAMA 2002;288:2123-2129.
4. Cholerton B, Gleason CE, Baker LD, Asthana S. Estrogen and Alzheimer’s disease: the story so far. Drugs Aging 2002;19:405-427.
5. Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women’s Health Initiative Memory Study: a randomized controlled trial. JAMA 2003;289:2651-2662.
6. Evans DA, Hebert LE, Beckett LA, et al. Education and other measures of socioeconomic status and risk of incident Alzheimer disease in a defined population of older persons. Arch Neurol 1997;54:1399-1405.
7. Huang X, Chen H, Miller WC, et al. Lower low-density lipoprotein cholesterol levels are associated with Parkinson’s disease. Mov Disord 2007;22:377-381.
8. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623-1630.
9. Gill TM, Robison JT, Tinetti ME. Predictors of recovery in activities of daily living among disabled older persons living in the community. J Gen Intern Med 1997;12:757-762.
10. Riekse RG, Li G, Petrie EC, et al. Effect of statins on Alzheimer’s disease biomarkers in cerebrospinal fluid. J Alzheimer Dis 2006;10:399-406.
11. Sparks DL, Sabbagh MN, Connor DJ, et al. Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch Neurol 2005;62:753-757.
12. Brass LM, Alberts MJ, Sparks L. An assessment of statin safety by neurologists. Am J Cardiol 2006;97:86C-88C.